Is Axogen (AXGN) Quietly Redefining Nerve Repair Moats With Avance and New Portfolio Backing?
TimesSquare Capital Management recently added Axogen (AXGN) to its U.S. Small Cap Growth Strategy after the company reported strong fourth-quarter 2025 revenue growth, driven by its peripheral nerve repair portfolio. A key factor is Axogen's Avance Nerve Graft, the only FDA-approved implantable biological nerve allograft, which recently received FDA approval for its Biologics License Application. This strengthens Axogen's position in the peripheral nerve regeneration market, though it introduces new operational and compliance demands.
SG Americas Securities LLC Increases Stock Holdings in AxoGen, Inc. $AXGN
SG Americas Securities LLC significantly increased its stake in AxoGen, Inc. in Q4, with institutional ownership nearing 80.29%. Despite largely positive Wall Street sentiment and a "Moderate Buy" consensus rating, AxoGen reported a slight EPS miss and remains unprofitable. The company's stock trades near $34.44, and analysts forecast a negative EPS for the current fiscal year.
AxoGen, Inc. $AXGN Shares Sold by JPMorgan Chase & Co.
JPMorgan Chase & Co. significantly reduced its stake in AxoGen, Inc. by 44.9% in the third quarter, selling 170,067 shares and retaining 209,003 shares valued at approximately $3.73 million. Despite this, institutional investors collectively own 80.29% of AxoGen, with several other funds adjusting their positions. AxoGen opened at $34.44, has a market cap of $1.79 billion, and holds a consensus analyst rating of "Moderate Buy" with a target price of $39.75.
AXGN PE Ratio & Valuation, Is AXGN Overvalued
AxoGen Inc (AXGN) is currently considered overvalued according to its forward PS ratio of 5.55, which is significantly higher than its five-year average. The fair price for AXGN, based on a relative valuation method, is estimated to be between $14.75 and $27.57, making the current price of $34.10 about 23.67% overvalued. Despite this, its P/S ratio of 5.55, which is 34.56% above the industry average, is deemed sustainable given its robust revenue growth of 21.25%.
What Makes Axogen (AXGN) an Investment Bet?
TimesSquare Capital Management's U.S. Small Cap Growth Strategy highlighted Axogen, Inc. (NASDAQ: AXGN) in its Q4 2025 investor letter, citing its novel therapies for peripheral nerve regeneration. The company's stock has seen significant gains, with a 97.07% increase over the past 52 weeks and a market capitalization of $1.74 billion. Despite its potential, the firm suggests that some AI stocks may offer higher returns in a shorter timeframe.
F&V Capital Management LLC Purchases Shares of 176,995 AxoGen, Inc. $AXGN
F&V Capital Management LLC acquired 176,995 shares of AxoGen, Inc. (AXGN) in Q4, valued at approximately $5.79 million, making it 0.9% of their portfolio. Other institutional investors also increased their holdings, with institutional ownership now at 80.29%. Despite missing Q4 EPS estimates, analysts maintain a "Moderate Buy" rating with a consensus price target of $39.75.
AXGN: Canaccord Genuity Maintains 'Buy' Rating with $40 Target | AXGN Stock News
Canaccord Genuity has maintained its 'Buy' rating for Axogen (AXGN) with an unchanged price target of $40, reflecting continued confidence in the company's market potential. This affirmation follows several recent positive analyst ratings, underscoring ongoing positive sentiment for Axogen's growth strategies. The consensus among 10 analysts projects an average target price of $40.80, suggesting an upside of 30.27% from the current price.
Is It Too Late To Consider Axogen (AXGN) After Its 75% One Year Surge?
Axogen (AXGN) has experienced a significant 75.9% surge over the last year, prompting a valuation analysis to determine if it's still offering value. While a Discounted Cash Flow model suggests Axogen is fairly valued, its Price-to-Sales ratio indicates it might be overvalued compared to its industry and Simply Wall St's proprietary Fair Ratio. Investors are encouraged to consider different narratives and future prospects to decide on the stock's attractiveness.
AXGN: Canaccord Genuity Maintains 'Buy' Rating with $40 Target
Canaccord Genuity analyst Caitlin Cronin has maintained a 'Buy' rating on Axogen (AXGN) with an unchanged price target of $40, reflecting continued confidence in the company's potential. This comes amidst several other recent positive analyst ratings and price target increases for Axogen. The company specializes in technologies for peripheral nerve regeneration and repair, with its products available internationally.
AxoGen's (AXGN) "Buy" Rating Reaffirmed at Canaccord Genuity Group
Canaccord Genuity Group reaffirmed its "Buy" rating on AxoGen (AXGN) with a $40 price target, suggesting a 28.76% upside. Despite this, AxoGen recently missed EPS estimates, reported negative net margin and ROE, and analysts forecast a negative EPS for the current year, indicating ongoing profitability challenges. The stock is trading around $31.07, with institutional investors owning approximately 80% of shares.
(AXGN) Price Dynamics and Execution-Aware Positioning
This article provides an analysis of Axogen Inc. (NASDAQ: AXGN) stock, highlighting strong sentiment across all horizons. It details several AI-generated trading strategies for different risk profiles, including position trading, momentum breakout, and risk hedging strategies. The analysis also includes multi-timeframe signal data and identifies specific support and resistance levels.
Vanguard realigns reporting; Axogen (NASDAQ: AXGN) shows 0 shares owned
The Vanguard Group has filed an amendment to its Schedule 13G for Axogen Inc (NASDAQ: AXGN), disclosing zero beneficial ownership of common stock. This change is due to an internal realignment on January 12, 2026, which prompted certain Vanguard subsidiaries to report separately. The filing clarifies that this is a reporting adjustment rather than a market trade or sale of shares.
Assessing Axogen (AXGN) Valuation After Growth Outlook And FDA Approval Fuel Strong One Year Share Price Gain
Axogen (AXGN) has seen significant share price appreciation over the past year, driven by expectations of 20% revenue growth in 2025, expanded reimbursement, FDA approval of a key nerve repair product, and anticipated positive free cash flow in 2026. While analysts see the stock as undervalued with a fair value of $40.56, its current P/S ratio of 7.5x is higher than the industry average, suggesting potential valuation risk if sentiment shifts. Investors are encouraged to review the company's financial data to form their own conclusions on its future prospects.
Assenagon Asset Management S.A. Purchases 90,777 Shares of AxoGen, Inc. $AXGN
Assenagon Asset Management S.A. increased its stake in AxoGen, Inc. (NASDAQ:AXGN) by 7.0% in Q4, acquiring an additional 90,777 shares, bringing its total ownership to 1,379,849 shares valued at $45.16 million. Despite a recent insider stock sale by Erick Wayne Devinney and a slight EPS miss, analyst sentiment remains largely positive with a "Moderate Buy" consensus and an average target price of $39.38. AxoGen, a medical technology company specializing in peripheral nerve damage solutions, holds a market capitalization of $1.69 billion.
Axogen spends $1.7M on another Vandalia site
Axogen, a biotechnology company, has acquired a new industrial property in Vandalia for nearly $1.7 million, further expanding its local footprint. This purchase adds an 11,378-square-foot building to its existing operations, which have grown significantly since its initial $5 million investment in 2018. The company recently reported strong financial results, with fourth-quarter 2025 revenue up 21.3% year-over-year.
Axogen Insider Sale of 5,221 Shares Follows 20% Revenue Growth in 2025. Here's What to Know
Axogen's Chief Innovation Officer sold 5,221 shares of common stock for approximately $171,000, representing 1.95% of his holdings. This transaction was related to the vesting and exercise of restricted stock units, with shares sold and withheld for tax obligations, indicating a routine compensation event rather than a change in company outlook. Axogen reported strong financial results in 2025 with 20.2% revenue growth and expects at least 18% growth in 2026, suggesting investors should focus on the company's operational performance.
This $6.5 Million Healthcare Trim Comes Amid a 71% Stock Surge and 20% Revenue Growth
DAFNA Capital Management sold 265,456 shares of Axogen (AXGN) in the fourth quarter for an estimated worth of $6.53 million, even as AXGN experienced a 71% stock surge and 20% revenue growth. This move is seen as portfolio rebalancing rather than a loss of confidence, as Axogen, a commercial-stage healthcare company, continues to show steady growth and improved prospects for scalability after recent FDA approval and reimbursement dynamics. The article suggests this makes Axogen a stable investment, though it was not among Motley Fool's top 10 stock picks.
DAFNA Capital Management Sells Axogen Shares in 2025 - News and Statistics
DAFNA Capital Management reduced its stake in Axogen Inc. during Q4 2025 by selling 265,456 shares valued at $6.53 million. Following this transaction, DAFNA still holds 476,826 Axogen shares worth $15.61 million, representing 3.63% of its reported assets. Axogen, a medical device company specializing in peripheral nerve repair products, has seen significant share price growth over the past year, outperforming the S&P 500, with current trading at $30.78 and a market capitalization of $1.6 billion.
This $6.5 Million Healthcare Reduction Follows a 71% Increase in Stock Price and 20% Rise in Revenue
DAFNA Capital Management reduced its stake in Axogen by $6.53 million, selling 265,456 shares in Q4 2025. This decision is seen as prudent portfolio management for diversification after Axogen's stock rose 71% in the past year and its revenue increased by 20%, rather than a lack of confidence in the company's future. Axogen, a medical technology firm specializing in peripheral nerve repair, is generating commercial revenue but is still working towards consistent profitability.
Axogen chief innovation officer DeVinney sells $171k in shares
Axogen's Chief Innovation Officer, Erick Wayne DeVinney, sold 5,221 shares of common stock for approximately $171,457 and disposed of 2,870 shares to cover tax obligations. Despite the stock's recent retreat, analysts maintain a bullish outlook with price targets between $39 and $43. The company also recently surpassed Q4 2025 earnings and revenue expectations.
Is It Too Late To Consider Axogen (AXGN) After Its Strong Three Year Run
This article evaluates Axogen (AXGN) following a significant three-year stock run and recent pullbacks, questioning if it's still a good value at US$30.94. Using discounted cash flow (DCF) analysis, the company appears fairly valued, but its Price-to-Sales (P/S) ratio suggests it's overvalued compared to industry peers. The analysis encourages investors to consider different narratives and financial metrics beyond just stock price movements.
Axogen chief innovation officer DeVinney sells $171k in shares
Axogen's Chief Innovation Officer, Erick Wayne DeVinney, sold 5,221 shares of common stock for approximately $171,457 and disposed of an additional 2,870 shares to cover tax obligations related to restricted stock units. Despite the sale, Axogen's stock has seen significant gains over the past year and analysts maintain a bullish outlook with price targets between $39 and $43. The company also recently reported strong fourth-quarter 2025 earnings, surpassing analyst expectations for both EPS and revenue.
Axogen (AXGN) officer nets shares after RSU vesting and sale
Axogen, Inc.'s Chief Innovation Officer, Erick Wayne DeVinney, engaged in transactions involving restricted stock units (RSUs) and common shares. On March 16, 2026, 17,938 RSUs vested, with 2,870 shares withheld for tax obligations at $32.84 per share. DeVinney also sold 5,221 common shares in an open-market transaction at the same price, and now directly holds 262,781 shares of Axogen common stock.
Erick Wayne Devinney Sells 5,221 Shares of AxoGen (NASDAQ:AXGN) Stock
Erick Wayne Devinney, an insider at AxoGen (NASDAQ:AXGN), recently sold 5,221 shares of the company's stock for approximately $171,458, reducing his stake by 1.95%. This transaction brings his total holdings to 262,781 shares, valued at about $8.63 million. AxoGen's stock has a "Moderate Buy" consensus rating from analysts with an average target price of $39.38, despite a recent earnings per share miss.
Axogen (AXGN) CFO nets shares from 9,000 RSU vesting as company withholds stock for taxes
Axogen, Inc. CFO Lindsey Marie Hartley reported the vesting of 9,000 restricted stock units (RSUs) on March 16, 2026. To cover tax obligations, the company withheld 3,542 shares at $32.84 per share, rather than Hartley selling them on the open market. After these transactions, Hartley directly holds 60,734 shares of Axogen common stock.
AxoGen, Inc. (NASDAQ:AXGN) Q4 2025 earnings call transcript
This is the Q4 2025 earnings call transcript for AxoGen, Inc. (NASDAQ:AXGN). This transcript provides a detailed record of the company's financial performance and discussions during the earnings call for the fourth quarter of 2025. It is a key resource for investors and analysts interested in AxoGen's recent financial results and future outlook.
Do Options Traders Know Something About Axogen Stock We Don't?
Options traders are showing significant interest in Axogen (AXGN) stock, as indicated by the high implied volatility in a specific call option. This suggests an expectation of a large price movement for the stock. Analysts also have an optimistic view of Axogen, with increased earnings estimates, potentially signaling a developing trading opportunity.
Do Options Traders Have Insights on Axogen Stock That We're Unaware Of?
Axogen, Inc. (AXGN) has shown unusual options activity, with high implied volatility in its April 17, 2026 $20.00 Call options, suggesting traders expect significant price movement. Despite carrying a Zacks Rank #3 (Hold), analysts have recently raised earnings projections for the company. This heightened activity, coupled with positive analyst sentiment, could indicate a potential trading opportunity for those proficient in options strategies.
Do Options Traders Have Insights on Axogen Stock That We're Unaware Of?
Axogen, Inc. (AXGN) has shown unusual options activity, with high implied volatility for its April 17, 2026 $20.00 Call options, suggesting traders anticipate significant stock movement. This comes as analysts have raised earnings projections for Axogen, potentially indicating a trading opportunity where experienced options traders might sell premium to profit from less dramatic actual stock movement. The article highlights that while implied volatility is important, it is only one factor to consider in options trading.
(AXGN) as a Liquidity Pulse for Institutional Tactics
This article provides an in-depth analysis of Axogen Inc. (NASDAQ: AXGN), highlighting a positive near-term sentiment within a long-term bullish outlook despite a mid-term weak bias. It details several AI-generated trading strategies including position trading, momentum breakout, and risk hedging, complete with entry zones, targets, and stop losses. The analysis also features a multi-timeframe signal breakdown for support and resistance levels.
AxoGen, Inc. $AXGN is First Light Asset Management LLC's Largest Position
First Light Asset Management LLC has significantly increased its stake in AxoGen (NASDAQ: AXGN), making it the firm's largest holding, now owning 12.59% of the company. Despite recent insider share sales by two directors, analyst sentiment remains largely positive with a "Moderate Buy" consensus and an average price target of $39.38. AxoGen, a medical technology company specializing in peripheral nerve damage solutions, reported a slight earnings miss but revenue met expectations in its latest quarterly report.
ArrowMark Colorado Holdings LLC Buys 332,498 Shares of AxoGen, Inc. $AXGN
ArrowMark Colorado Holdings LLC increased its stake in AxoGen, Inc. by 20.4%, purchasing an additional 332,498 shares and bringing its total ownership to 1,958,406 shares valued at $34,938,000. Other institutional investors also adjusted their positions in the medical equipment provider. AxoGen has seen some insider selling, while analyst ratings generally recommend a "Buy" with an average price target of $39.38.
AXGN SEC Filings - Axogen Inc 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for investors to access Axogen Inc.'s SEC filings, including 10-K, 10-Q, and 8-K forms, along with AI-assisted summaries. The content highlights recent insider trading activities, the extension of the FDA's PDUFA date for Avance Nerve Graft to December 5, 2025, and details quarterly earnings reports. It also offers insights into the company's financial performance, regulatory milestones, and corporate governance.
A Look At Axogen (AXGN) Valuation After AVANCE BLA Approval And Updated Growth Outlook
Axogen (AXGN) is gaining investor attention following its AVANCE nerve graft BLA approval, improved balance sheet, and accelerating commercial momentum. While a popular narrative suggests the stock is 19% undervalued with a fair value of $39.20, its high P/S ratio of 7.3x (compared to an industry average of 2.8x) indicates expectations might already be high. Investors are encouraged to review the full data, considering both growth potential and execution risks as Axogen expands into new markets.
Should Axogen’s 2026 Growth Guidance Amid Wider Losses Require Action From Axogen (AXGN) Investors?
Axogen (AXGN) reported increased sales to US$225.21 million in 2025, but its net loss widened to US$15.70 million. Despite these losses, the company issued 2026 guidance forecasting at least 18% revenue growth to US$265.70 million, driven by strong demand for its nerve repair products. Investors are left to weigh this growth outlook against continued operating losses, shareholder dilution from a recent equity raise, and the need for sustained profitability.
Should Axogen’s 2026 Growth Guidance Amid Wider Losses Require Action From Axogen (AXGN) Investors?
Axogen (AXGN) reported increased sales in 2025 but also wider net losses, with basic loss per share rising to US$0.34. Despite the losses, the company issued 2026 guidance projecting at least 18% revenue growth, suggesting management confidence in its nerve repair portfolio. Investors need to weigh this growth outlook against continued operating losses and potential shareholder dilution from recent capital raises.
AxoGen Conference: AVANCE BLA Approval, Debt Paydown Fuel 2026 Growth Target of 18%+
AxoGen executives detailed their 2026 growth strategy, targeting at least 18% top-line growth, driven by commercial momentum, recent balance sheet improvements including a $142 million capital raise to eliminate debt, and the operational efficiencies from the AVANCE Biologics License Application (BLA) approval. While the BLA doesn't immediately unlock new patients, it allows for re-engagement with current users, operational streamlining, and re-evaluation with key payers that previously deemed the product experimental. The company also highlighted a positive reimbursement change for nerve care in outpatient settings and future gross margin improvements from manufacturing efficiencies.
Should Axogen’s 2026 Growth Guidance Amid Wider Losses Require Action From Axogen (AXGN) Investors?
Axogen, Inc. reported increased sales in 2025 but also widened net losses. The company issued 2026 guidance forecasting at least 18% revenue growth and stable gross margins, indicating confidence in its nerve repair portfolio. Investors are urged to consider whether this growth outlook justifies the continued operating losses and potential shareholder dilution, especially in light of a recent equity raise.
AxoGen at Leerink Conference: Strategic Growth and Market Expansion
AxoGen Inc. presented its strategic growth and market expansion plans at the Leerink Global Healthcare Conference 2026. The company highlighted successful debt elimination, strong revenue growth exceeding 20% in late 2025, and projected at least 18% growth for 2026, driven by market development and expansion into new areas like prostate care. The recent BLA approval for AVANCE is expected to streamline operations and support payer re-engagement for broader commercial coverage.
Axogen (AXGN) CMO granted 23,000 RSUs and adjusts share holdings
Axogen, Inc.'s Chief Marketing Officer, Jens Kemp, received 23,000 restricted stock units (RSUs) and 50,670 shares of common stock on February 26, 2026. To cover tax withholding from vesting equity awards, Axogen withheld 15,414 shares at $31.90 and 2,952 shares at $30.65. Following these transactions and a correction of a prior overstatement, Kemp now directly holds 76,451 shares of common stock and 23,000 RSUs.
AxoGen Touts FDA BLA Win, Targets 18% Growth and Wider Nerve Repair Adoption
AxoGen (NASDAQ:AXGN) recently presented at the Raymond James Institutional Investors Conference, detailing its ambition to establish peripheral nerve function restoration as a standard of care. The company highlighted its growth expectations, progress in reimbursement, and the significant implications of its recently acquired FDA Biologics License Application (BLA) for its AVANCE Nerve Graft. AxoGen aims for 15% to 20% growth over the next three to five years by focusing on extremities, breast reconstruction, and oral maxillofacial/head and neck markets, with potential expansion into prostate care.
(AXGN) Risk Channels and Responsive Allocation
This article provides an analysis of Axogen Inc. (NASDAQ: AXGN), highlighting weak near and mid-term sentiment but a positive long-term outlook. It details various trading strategies including position, momentum breakout, and risk hedging, along with specific entry, target, and stop-loss levels. The piece also presents AI-generated signals and multi-timeframe analysis for the stock.
Royce & Associates LP Purchases New Shares in AxoGen, Inc. $AXGN
Royce & Associates LP has acquired a new position in AxoGen, Inc. (NASDAQ:AXGN) during the third quarter, purchasing 201,044 shares valued at approximately $3.59 million. Other institutional investors have also adjusted their holdings, with AxoGen's stock price and earnings performance detailed alongside recent insider sales and analyst ratings. The company, which specializes in surgical solutions for peripheral nerve damage, reported Q3 earnings per share of $0.07, missing consensus estimates.
Axogen (AXGN) innovation chief reports stock awards and tax-share withholding
Axogen, Inc.'s Chief Innovation Officer, Erick Wayne DeVinney, reported receiving 23,000 restricted stock units and 33,780 shares of common stock as awards on February 26, 2026, with no cash cost. The report also detailed the disposition of 11,276 and 10,702 shares for tax withholding purposes related to the vesting of performance and restricted stock units, clarifying that no shares were sold by DeVinney. The restricted stock units are set to fully vest by February 26, 2030, with a phased vesting schedule.
Axogen (NASDAQ: AXGN) EVP reports RSU vesting and tax share withholding
Axogen, Inc.'s EVP and General Counsel, Marc A. Began, reported several equity compensation transactions including a grant of 23,000 restricted stock units (RSUs) vesting through February 26, 2030. Additionally, performance stock units and RSUs vested, leading to the acquisition of 11,250 common shares, with 8,753 shares at $31.90 and 4,427 shares at $30.65 withheld for tax liabilities. The filing explicitly states that Began did not sell any shares.
Why Axogen (AXGN) Is Down 10.1% After Avance FDA Win and 2026 Guidance Shift
Axogen (AXGN) experienced a stock drop despite FDA approval for its Avance product, which offers 12 years of market exclusivity, and positive 2026 revenue growth guidance. The decline is attributed to a wider net loss and increased spending, highlighting investor focus on the path to sustainable profitability and positive cash flow amidst the promising, yet single-product-reliant, biologic nerve repair franchise. Analysts predict a fair value of $37.33, suggesting an 18% upside.
Wall Street Zen Downgrades AxoGen (NASDAQ:AXGN) to Buy
Wall Street Zen has downgraded AxoGen (NASDAQ:AXGN) from a "strong-buy" to a "buy" rating, despite generally positive analyst sentiment with an average "Moderate Buy" rating and a price target of $37.67. The company recently missed EPS estimates, reporting ($0.28) against a consensus of $0.08, though revenue matched expectations. Insider selling has been observed with 301,680 shares sold in the last 90 days, including by the CEO and a director, while institutional ownership remains high at 80.29%.
AxoGen, Inc. (AXGN) Stock Analysis: Strong Buy Ratings Signal A 22.88% Upside Potential
AxoGen, Inc. (NASDAQ: AXGN), a medical device company specializing in peripheral nerve regeneration, shows significant investor interest with a market cap of $1.6 billion. Despite some mixed valuation metrics and challenges in performance, the company exhibits strong revenue growth and financial resilience. Analysts unanimously recommend a "Buy" rating, projecting a 22.88% upside potential, indicating a bullish outlook for the stock.
Axogen (NASDAQ: AXGN) CEO granted 98,000 RSUs vesting through 2030
Axogen, Inc.'s CEO, Michael D. Dale, was granted 98,000 Restricted Stock Units (RSUs) on February 26, 2026. These RSUs will vest over four years, with 50% vesting on February 26, 2028, and the remaining 50% vesting in two 25% tranches on February 26, 2029, and February 26, 2030. This equity award aligns his compensation with the company's long-term stock performance.
Axogen (AXGN) Valuation Check After FDA Avance Approval And New 2026 Growth Targets
Axogen (AXGN) recently secured FDA approval for Avance, a significant milestone for peripheral nerve repair, accompanied by 12 years of market exclusivity and new 2026 sales guidance. Despite recent share price fluctuations, the stock has shown strong long-term momentum. Simply Wall St's analysis suggests Axogen is currently undervalued by 14.6%, trading at $31.90 against a fair value of $37.33, though its P/S ratio indicates higher pricing compared to industry averages.
